In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

Drugmaker Eli Lilly said Thursday that things are looking good for their latest weight loss drug that would be available as a ...

Eli Lilly, the maker of Zepbound and Mounjaro, said its experimental GLP-1 pill successfully helped adults with obesity lose weight in a Phase 3 trial, as the company moves closer to submitting the ...

Emmy Nominees In Comedy Casting Sound Off On Self Tapes, Future Of Their Jobs & Whether Trump's Assault On DEI Should Worry Hollywood ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

Fortinet, AppLovin, Airbnb, Duolingo and more stock were making big moves Thursday after the companies reported quarterly ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Kym Whitley partners with Eli Lilly to share her transformative experience using Zepbound, an obesity management medication.

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may ...

Despite significant advances in early detection, surgery, radiotherapy, and systemic treatment of breast cancer, late relapse ...